Streetbeat News

IDRSF

Idorsia Ltd

https://www.idorsia.com

CEO

Jean-Paul Clozel

Industry

Pharmaceutical Preparation Manufacturing

Open

2.25

Mkt cap

180M

Volume

1.5K

High

2.25

P/E Ratio

5.26

52-wk high

2.88

Low

1.00

Div yield

N/A

52-wk low

1.00

Idorsia's TRYVIO, a once-daily dual endothelin receptor antagonist, is now available in the U.S. for treating difficult-to-control hypertension. It is designed to be used alongside other antihypertensive drugs for patients not adequately controlled on existing medications.

Portfolio Pulse from

November 15, 2024 | 1:15 pm

Idorsia Ltd is set to present new data on aprocitentan, a dual endothelin receptor antagonist for treating systemic hypertension, at the 2024 American Heart Association Scientific Sessions.

Portfolio Pulse from

November 11, 2024 | 5:00 pm

Viatris and Idorsia have announced a significant global R&D collaboration, expanding Viatris' portfolio with two Phase 3 assets, Selatogrel and Cenerimod, both with high revenue potential. The collaboration leverages Viatris' financial strength and global operations with Idorsia's drug development expertise. The deal highlights Viatris' disciplined capital allocation and includes options for future asset expansions. A special R&D event by Viatris is scheduled for March 27, 2024.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 8:12 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.